Hepatocellular Carcinoma Risk According to Regimens for Eradication of Hepatitis C Virus; Interferon or Direct Acting Antivirals.

摘要: By pegylated interferon (PegIFN)-free direct-acting antivirals (DAAs) against hepatitis C virus (HCV) infection, a sustained virological response (SVR) rate >95% can be attained with satisfactory tolerability and shorter treatment duration. However, it remains controversial whether there is any difference in prognosis depending on regimens-PegIFN or DAAs. We compared the probabilities of hepatocellular carcinoma (HCC) development between patients achieving an SVR by PegIFN/ribavirin (PegIFN group, n = 603) DAAs (DAAs 479). The group was significantly older had higher proportion cirrhosis than PegIFN group. Before adjustment, HCC incidence (p < 0.001). multivariate analyses, (vs. PegIFN) not associated risk (adjusted hazard ratio 0.968, 95% confidence interval 0.380-2.468; p 0.946). Old age, male, body mass index, cirrhosis, lower platelet count were increased (all 0.05). After propensity score matching (PSM), similar two groups observed 0.372). also incidences according to sofosbuvir (SOF)-based SOF-free DAAs, showing both before adjustment 0.478) after PSM 0.855). In conclusion, post-SVR risks comparable regimens; PegIFN- vs. DAA-based regimens SOF-based DAA regimens. Further studies longer follow-up period are required.